
Orion Oyj
Orion Oyj is a Finland-based company in the Healthcare sector with a market capitalisation of $13.8B. Its FinScore is 69/100; its highest-scoring layer is Momentum (84) and its lowest is Value (44). The shares trade at 21.0x trailing earnings and are up 39% year to date.
Share price performance
About Orion Oyj
www.orionpharma.comOrion Oyj is a global pharmaceutical company engaged in the research, development, manufacturing, and commercialization of human and veterinary medicines, alongside active pharmaceutical ingredients (APIs). Its market reach extends across Finland, the Nordic countries, wider Europe, North America, and other international territories. The company's human health division offers both prescription drugs and self-care products. Its key prescription medications include Nubeqa for prostate cancer treatment, dexdor and Precedex for intensive care sedation, and therapies like Stalevo and Comtess/Comtan for Parkinson's disease. Other significant human products are Simdax for acute decompensated heart failure and Fareston for breast cancer. Orion also provides a comprehensive suite of Easyhaler-branded drugs, such as Salmeterol/fluticasone, Budesonide/formoterol, Formoterol, Budesonide, Beclomet, and Buventol, all designed to treat asthma and chronic obstructive pulmonary disease (COPD). In the animal health sector, Orion offers veterinary pharmaceuticals including Bonqat, Clevor, Domosedan, Domitor, Antisedan, Dexdomitor, Domosedan Gel, Sileo, and Tessie. Beyond its own product line, the company manufactures APIs for both generic and proprietary drugs and provides contract manufacturing services. Orion also acts as a distributor, marketing and selling veterinary medicines produced by other international companies. Its customer base is broad, serving various healthcare providers and professionals, including specialist and general practitioners, veterinarians, pharmacies, hospitals, healthcare centers, clinics, and laboratories, as well as direct consumers with pets. Orion Oyj fosters strategic partnerships, notably with Propeller Health to embed connectivity into its Easyhaler® portfolio for asthma and COPD, and a research collaboration and license agreement with Alligator Bioscience AB (publ) focusing on the discovery and advancement of innovative bispecific antibody cancer therapeutics. Founded in 1917, Orion Oyj is headquartered in Espoo, Finland.
- Sector
- Healthcare
- Industry
- Drug Manufacturers - General
- HQ
- Finland
- Fiscal year-end
- December
- Trading currency
- EUR
- Reporting currency
- EUR
- Fundamentals updated
- 91 days ago
- Market cap
- $13.8B
- Shares outstanding
- 140.4M
- P/E (TTM)
- 21.0x
- Dividend yield (TTM)
- 1.96%
- Beta (issuer)
- 0.28
- Revenue (latest FY)
- €1.9B
Revenue breakdown
Revenue split not available
FinScore
As of 2026-10-19Snapshot
Ownership
Holder data is not available for this company yet.
Sign up or log in to see Analysis
Analysis for Orion Oyj is available to Finryse members. The Overview stays open to everyone; creating an account is free.
Sign up or log in to see Financials
Financials for Orion Oyj is available to Finryse members. The Overview stays open to everyone; creating an account is free.
Sign up or log in to see Estimates
Estimates for Orion Oyj is available to Finryse members. The Overview stays open to everyone; creating an account is free.
Sign up or log in to see Peers
Peers for Orion Oyj is available to Finryse members. The Overview stays open to everyone; creating an account is free.
Sign up or log in to see Valuation
Valuation for Orion Oyj is available to Finryse members. The Overview stays open to everyone; creating an account is free.
Sign up or log in to see News
News for Orion Oyj is available to Finryse members. The Overview stays open to everyone; creating an account is free.